替雷利珠单抗治疗晚期非小细胞肺癌的药学监护路径构建与实践OA
Development and implementation of a clinical pharmacist intervention strategy for tislelizumab in the treatment of advanced non-small cell lung cancer
目的 构建替雷利珠单抗注射液治疗晚期非小细胞肺癌(NSCLC)的药学监护路径,并观察实践效果.方法 将我院接诊的晚期NSCLC患者分为对照组和试验组.对照组实行常规药学监护,试验组实行药学监护路径.比较2组的治疗有效性、免疫相关药物不良事件(irAEs)发生率、≥3级irAEs发生率、治疗相关停药率、用药依从性、生活质量及药学服务满意度.结果 共纳入106例患者,其中对照组和试验组各53例.治疗后,试验组和对照组的客观缓解率(ORR)分别为47.17％和28.30％,疾病控制率(DCR)分别为60.38％和39.62％,试验组的上述指标均显著高于对照组(均P＜0.05).试验组和对照组的irAEs发生率分别为39.62％和60.38％,≥3级irAEs发生率分别为13.21％和30.19％,治疗相关停药率及分别为9.43％和24.53％,试验组的上述指标均显著低于对照组(均P＜0.05).治疗后,试验组和对照组的欧洲癌症研究与试验组织生活质量问卷肺癌模块(EORTC QLQ-LC13)评分分别为(50.15±9.06)和(53.94±7.19)分,试验组显著低于对照组(P＜0.05).试验组的药学服务满意度为90.57％,显著高于对照组的75.47％(P＜0.05).结论 药学监护路径可以提高替雷利珠单抗注射液用药依从性,减少免疫相关药物不良事件及治疗中断,改善生活质量并提升药学服务满意度,从而有助于患者临床获益.
Objective To construct a clinical pharmacist intervention strategy for tislelizumab injection in the treatment of advanced non-small cell lung cancer(NSCLC)and evaluate its practical effects.Methods Patients with advanced NSCLC admitted to our hospital were divided into control group and treatment group.The control group received routine pharmaceutical care,while the treatment group received a clinical pharmacist intervention strategy.Therapeutic efficacy,incidence of immune-related adverse events(irAEs),incidence of grade ≥ 3 irAEs,treatment-related drug withdrawal rate,medication adherence,quality of life and satisfaction with pharmaceutical care were compared between the two groups.Results A total of 106 patients were included,including 53 in control group and 53 in treatment group.After treatment,the objective response rates(ORR)of treatment group and control group were 47.17％and 28.30％,respectively;the disease control rates(DCR)were 60.38％and 39.62％,respectively.The above indicators in treatment group were statistically significantly higher than those in control group(all P＜0.05).The incidences of irAEs in treatment group and control group were 39.62％and 60.38％,respectively;the incidences of irAEs ≥ grade 3 were 13.21％and 30.19％,respectively;the treatment-related discontinuation rates were 9.43％and 24.53％,respectively.The above indicators in treatment group were statistically significantly lower than those in control group(all P＜0.05).After treatment,the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-lung cancer 13(EORTC QLQ-LC13)scores for treatment group and control group were(50.15±9.06)and(53.94±7.19)points,respectively,with treatment group statistically significantly lower than control group(P＜0.05).The satisfaction rate of pharmaceutical services in treatment group was 90.57％,statistically significantly higher than control group's 75.47％(P＜0.05).Conclusion The clinical pharmacist intervention strategy can improve medication adherence to tislelizumab injection,reduce immune-related adverse events and treatment interruption,improve quality of life,and enhance satisfaction with pharmaceutical care,thereby contributing to better clinical outcomes.
刘莫愁;姜道利;季磊
徐州医科大学附属医院药学部,江苏徐州 221006徐州医科大学附属医院药学部,江苏徐州 221006徐州医科大学附属医院呼吸与危重症医学科,江苏徐州 221006
医药卫生
替雷利珠单抗注射液肺癌药学监护生活质量
tislelizumab injectionlung cancerclinical pharmacist intervention strategyquality of life
《中国临床药理学杂志》 2026 (5)
720-726,7
江苏省高校重点实验室开放课题基金资助项目(XZSYSKF2024015)
评论